“Hep C, where art thou”: What are the remaining (fundable) questions in hepatitis C virus research?

Hepatology

Volumn 65, Issue 1, 2017, Pages 341-349

  Rosen, Hugo Ramón ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; HEPATITIS C VACCINE; NEUTRALIZING ANTIBODY; VIRUS GLYCOPROTEIN; HEPATITIS VACCINE;

ANTIVIRAL THERAPY; ARTICLE; CLINICAL TRIAL; DISEASE COURSE; DISEASE ELIMINATION; DRUG TREATMENT FAILURE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; NONHUMAN; PRIORITY JOURNAL; VACCINATION; VIRAL CLEARANCE; ECONOMICS; FINANCIAL MANAGEMENT; HEPACIVIRUS; HEPATITIS C, CHRONIC; MEDICAL RESEARCH; RISK; TREATMENT FAILURE;

ANTIBODIES, NEUTRALIZING; ANTIVIRAL AGENTS; BIOMEDICAL RESEARCH; DISEASE PROGRESSION; FINANCIAL MANAGEMENT; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; RISK; TREATMENT FAILURE; VIRAL HEPATITIS VACCINES;

EID: 85006036905     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.28848     Document Type: Article

References (88)

1. Ward JW. Hepatitis C virus: the 25-year journey from discovery to cure. Hepatology 2014;60:1479–1482.
2. Sorrell MF. Hepatitis C recurrence after liver transplantation: is there cause for concern? Am J Gastroenterol 1997;92:1416–1417.
3. Missale G, Bertoni R, Lamonaca V, Valli A, Massari M, Mori C, et al. Different clinical behaviors of acute hepatitis C virus infection are associated with different vigor of the anti-viral cell-mediated immune response. J Clin Invest 1996;98:706–714.
4. Mahajan R, Xing J, Liu SJ, Ly KN, Moorman AC, Rupp L, et al. Mortality among persons in care with hepatitis C virus infection: the Chronic Hepatitis Cohort Study (CHeCS), 2006-2010. Clin Infect Dis 2014;58:1055–1061.
5. Chhatwal J, Wang X, Ayer T, Kabiri M, Chung RT, Hur C, et al. Hepatitis C disease burden in the United States in the era of oral direct-acting antivirals. Hepatology 2016;64:1442–1450.
6. Davis GL, Alter MJ, El-Serag H, Poynard T, Jennings LW. Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression. Gastroenterology 2010;138:513–521, 521.e1-6.
7. Terrault N. Liver transplantation in the setting of chronic HCV. Best Pract Res Clin Gastroenterol 2012;26:531–548.
8. Thomas DL. Global control of hepatitis C: where challenge meets opportunity. Nat Med 2013;19:850–858.
9. AASLD/IDSA HCV Guidance Panel. Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus. Hepatology 2015;62:932–954.
10. Najafzadeh M, Andersson K, Shrank WH, Krumme AA, Matlin OS, Brennan T, et al. Cost-effectiveness of novel regimens for the treatment of hepatitis C virus. Ann Intern Med 2015;162:407–419.
11. van der Meer AJ, Veldt BJ, Feld JJ, Wedemeyer H, Dufour JF, Lammert F, et al. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA 2012;308:2584–2593.
12. van der Meer AJ. Achieving sustained virological response: what's the impact on further hepatitis C virus-related disease? Expert Rev Gastroenterol Hepatol 2015;9:559–566.
13. Innes HA, McDonald SA, Dillon JF, Allen S, Hayes PC, Goldberg D, et al. Toward a more complete understanding of the association between a hepatitis C sustained viral response and cause-specific outcomes. Hepatology 2015;62:355–364.
14. Hsu YC, Ho HJ, Huang YT, Wang HH, Wu MS, Lin JT, Wu CY. Association between antiviral treatment and extrahepatic outcomes in patients with hepatitis C virus infection. Gut 2015;64:495–503.
15. Backus LI, Boothroyd DB, Phillips BR, Belperio P, Halloran J, Mole LA. A sustained virologic response reduces risk of all-cause mortality in patients with hepatitis C. Clin Gastroenterol Hepatol 2011;9:509–516.e1.
16. Meissner EG, Wu D, Osinusi A, Bon D, Virtaneva K, Sturdevant D, et al. Endogenous intrahepatic IFNs and association with IFN-free HCV treatment outcome. J Clin Invest 2014;124:3352–3363.
17. Negash AA, Ramos HJ, Crochet N, Lau DT, Doehle B, Papic N, et al. IL-1beta production through the NLRP3 inflammasome by hepatic macrophages links hepatitis C virus infection with liver inflammation and disease. PLoS Pathog 2013;9:e1003330.
18. Giugliano S, Kriss M, Golden-Mason L, Dobrinskikh E, Stone AE, Soto-Gutierrez A, et al. Hepatitis C virus infection induces autocrine interferon signaling by human liver endothelial cells and release of exosomes, which inhibits viral replication. Gastroenterology 2015;148:392–402.e13.
19. Vercauteren K, de Jong YP, Meuleman P. Animal models for the study of HCV. Curr Opin Virol 2015;13:67–74.
20. Rongvaux A, Willinger T, Martinek J, Strowig T, Gearty SV, Teichmann LL, et al. Development and function of human innate immune cells in a humanized mouse model. Nat Biotechnol 2014;32:364–372.
21. Charlton M, Everson GT, Flamm SL, Kumar P, Landis C, Brown RS, Jr., et al. Ledipasvir and sofosbuvir plus ribavirin for treatment of HCV infection in patients with advanced liver disease. Gastroenterology 2015;149:649–659.
22. Deterding K, Honer Zu Siederdissen C, Port K, Solbach P, Sollik L, Kirschner J, et al. Improvement of liver function parameters in advanced HCV-associated liver cirrhosis by IFN-free antiviral therapies. Aliment Pharmacol Ther 2015;42:889–901.
23. Modi AA, Nazario H, Trotter JF, Gautam M, Weinstein J, Mantry P, et al. Safety and efficacy of simeprevir plus sofosbuvir with or without ribavirin in patients with decompensated genotype 1 hepatitis C cirrhosis. Liver Transpl 2016;22:281–286.
24. Saxena V, Nyberg L, Pauly M, Dasgupta A, Nyberg A, Piasecki B, et al. Safety and efficacy of simeprevir/sofosbuvir in hepatitis C-infected patients with compensated and decompensated cirrhosis. Hepatology 2015;62:715–725.
25. Manns M, Samuel D, Gane EJ, Mutimer D, McCaughan G, Buti M, et al. Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 trial. Lancet Infect Dis 2016;16:685–697.
26. Belli LS, Berenguer M, Cortesi PA, Strazzabosco M, Rockenschaub SR, Martini S, et al.; European Liver and Intestine Association (ELITA). Delisting of liver transplant candidates with chronic hepatitic C after viral eradication: a European study. J Hepatol 2016;65:524–531.
27. Di Marco V, Calvaruso V, Ferraro D, Bavetta MG, Cabibbo G, Conte E, et al. Effects of viral eradication in patients with hepatitis C Virus and cirrhosis differ with stage of portal hypertension. Gastroenterology 2016;151:130–139.e2.
28. Mandorfer M, Kozbial K, Schwabl P, Freissmuth C, Schwarzer R, Stern R, et al. Sustained virologic response to interferon-free therapies ameliorates HCV-induced portal hypertension. J Hepatol 2016;65:692–699.
29. Shirabe K, Sugimachi K, Harada N, Kayashima H, Maeda T, Tsujita E, et al. Favorable prognosis in patients with sustained virological response to antiviral therapy, including interferon, for chronic hepatitis C before hepatic resection for hepatocellular carcinoma. Anticancer Res 2015;35:6963–6969.
30. Sarrazin C. The importance of resistance to direct antiviral drugs in HCV infection in clinical practice. J Hepatol 2016;64:486–504.
31. Chen ZW, Li H, Ren H, Hu P. Global prevalence of pre-existing HCV variants resistant to direct-acting antiviral agents (DAAs): mining the GenBank HCV genome data. Sci Rep 2016;6:20310.
32. Feld JJ, Zeuzem S. Sofosbuvir and velpatasvir for patients with HCV infection. N Engl J Med 2016;374:1688–1689.
33. Mailly L, Xiao F, Lupberger J, Wilson GK, Aubert P, Duong FH, et al. Clearance of persistent hepatitis C virus infection in humanized mice using a claudin-1-targeting monoclonal antibody. Nat Biotechnol 2015;33:549–554.
34. Rich JD, Taylor LE. The beginning of a new era in understanding hepatitis C virus prevention. J Infect Dis 2010;202:981–983.
35. Page-Shafer K, Hahn JA, Lum PJ. Preventing hepatitis C virus infection in injection drug users: risk reduction is not enough. AIDS 2007;21:1967–1969.
36. Paintsil E, He H, Peters C, Lindenbach BD, Heimer R. Survival of hepatitis C virus in syringes: implication for transmission among injection drug users. J Infect Dis 2010;202:984–990.
37. Nelson PK, Mathers BM, Cowie B, Hagan H, Des Jarlais D, Horyniak D, Degenhardt L. Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews. Lancet 2011;378:571–583.
38. Grebely J, Dore GJ. Prevention of hepatitis C virus in injecting drug users: a narrow window of opportunity. J Infect Dis 2011;203:571–574.
39. Mehta SH, Astemborski J, Kirk GD, Strathdee SA, Nelson KE, Vlahov D, Thomas DL. Changes in blood-borne infection risk among injection drug users. J Infect Dis 2011;203:587–594.
40. MacArthur GJ, van Velzen E, Palmateer N, Kimber J, Pharris A, Hope V, et al. Interventions to prevent HIV and hepatitis C in people who inject drugs: a review of reviews to assess evidence of effectiveness. Int J Drug Policy 2014;25:34–52.
41. Palmateer N, Kimber J, Hickman M, Hutchinson S, Rhodes T, Goldberg D. Evidence for the effectiveness of sterile injecting equipment provision in preventing hepatitis C and human immunodeficiency virus transmission among injecting drug users: a review of reviews. Addiction 2010;105:844–859.
42. Wright NM, Tompkins CN. A review of the evidence for the effectiveness of primary prevention interventions for hepatitis C among injecting drug users. Harm Reduct J 2006;3:27.
43. Klevens RM, Hu DJ, Jiles R, Holmberg SD. Evolving epidemiology of hepatitis C virus in the United States. Clin Infect Dis 2012;55(Suppl 1):S3–S9.
44. Magiorkinis G, Sypsa V, Magiorkinis E, Paraskevis D, Katsoulidou A, Belshaw R, et al. Integrating phylodynamics and epidemiology to estimate transmission diversity in viral epidemics. PLoS Comput Biol 2013;9:e1002876.
45. Bruggmann P. Treatment as prevention: the breaking of taboos is required in the fight against hepatitis C among people who inject drugs. Hepatology 2013;58:1523–1525.
46. Aspinall EJ, Corson S, Doyle JS, Grebely J, Hutchinson SJ, Dore GJ, et al. Treatment of hepatitis C virus infection among people who are actively injecting drugs: a systematic review and meta-analysis. Clin Infect Dis 2013;57(Suppl 2):S80–89.
47. Cousien A, Tran VC, Deuffic-Burban S, Jauffret-Roustide M, Dhersin JS, Yazdanpanah Y. Hepatitis C treatment as prevention of viral transmission and liver-related morbidity in persons who inject drugs. Hepatology 2016;63:1090–1101.
48. Hopkins DR. Disease eradication. N Engl J Med 2013;368:54–63.
49. Kwiatkowski CF, Fortuin Corsi K, Booth RE. The association between knowledge of hepatitis C virus status and risk behaviors in injection drug users. Addiction 2002;97:1289–1294.
50. Corso KA, Bryan CJ, Corso ML, Kanzler KE, Houghton DC, Ray-Sannerud B, Morrow CE. Therapeutic alliance and treatment outcome in the primary care behavioral health model. Fam Syst Health 2012;30:87–100.
51. Hellard M, Doyle JS, Sacks-Davis R, Thompson AJ, McBryde E. Eradication of hepatitis C infection: the importance of targeting people who inject drugs. Hepatology 2014;59:366–369.
52. + T cells associated with reversible immune dysfunction. J Virol 2007;81:9249–9258.
53. Radziewicz H, Ibegbu CC, Fernandez ML, Workowski KA, Obideen K, Wehbi M, et al. Liver-infiltrating lymphocytes in chronic human hepatitis C virus infection display an exhausted phenotype with high levels of PD-1 and low levels of CD127 expression. J Virol 2007;81:2545–2553.
54. Attanasio J, Wherry EJ. Costimulatory and coinhibitory receptor pathways in infectious disease. Immunity 2016;44:1052–1068.
55. + HCV-specific human CTLs is associated with viral persistence, and its blockade restores hepatocyte-directed in vitro cytotoxicity. J Clin Invest 2010;120:4546–4557.
56. Burchill MA, Golden-Mason L, Wind-Rotolo M, Rosen HR. Memory re-differentiation and reduced lymphocyte activation in chronic HCV-infected patients receiving direct-acting antivirals. J Viral Hepat 2015;22:983–991.
57. + T cell function by interferon-free therapy. J Hepatol 2014;61:538–543.
58. Youngblood B, Noto A, Porichis F, Akondy RS, Ndhlovu ZM, Austin JW, et al. Cutting edge: Prolonged exposure to HIV reinforces a poised epigenetic program for PD-1 expression in virus-specific CD8 T cells. J Immunol 2013;191:540–544.
59. Patient-centered models of HCV care for people who inject drugs. Available at: http://www.pcori.org/research-results/2015/patient-centered-models-hcv-care-people-who-inject-drugs. Accessed November 1, 2016.
60. Rosen HR. Emerging concepts in immunity to hepatitis C virus infection. J Clin Invest 2013;123:4121–4130.
61. Barnes D, Kunitomi M, Vignuzzi M, Saksela K, Andino R. Harnessing endogenous miRNAs to control virus tissue tropism as a strategy for developing attenuated virus vaccines. Cell Host Microbe 2008;4:239–248.
62. Ansaldi F, Orsi A, Sticchi L, Bruzzone B, Icardi G. Hepatitis C virus in the new era: perspectives in epidemiology, prevention, diagnostics and predictors of response to therapy. World J Gastroenterol 2014;20:9633–9652.
63. Honegger JR, Zhou Y, Walker CM. Will there be a vaccine to prevent HCV infection? Semin Liver Dis 2014;34:79–88.
64. Ogholikhan S, Schwarz KB. Hepatitis vaccines. Vaccines (Basel) 2016;4. pii: E6. doi: 10.3390/vaccines4010006.
65. Sabo MC, Luca VC, Prentoe J, Hopcraft SE, Blight KJ, Yi M, et al. Neutralizing monoclonal antibodies against hepatitis C virus E2 protein bind discontinuous epitopes and inhibit infection at a postattachment step. J Virol 2011;85:7005–7019.
66. Liang TJ. Current progress in development of hepatitis C virus vaccines. Nat Med 2013;19:869–878.
67. Folgori A, Capone S, Ruggeri L, Meola A, Sporeno E, Ercole BB, et al. A T-cell HCV vaccine eliciting effective immunity against heterologous virus challenge in chimpanzees. Nat Med 2006;12:190–197.
68. Barnes E, Folgori A, Capone S, Swadling L, Aston S, Kurioka A, et al. Novel adenovirus-based vaccines induce broad and sustained T cell responses to HCV in man. Sci Transl Med 2012;4:115ra111.
69. Swadling L, Capone S, Antrobus RD, Brown A, Richardson R, Newell EW, et al. A human vaccine strategy based on chimpanzee adenoviral and MVA vectors that primes, boosts, and sustains functional HCV-specific T cell memory. Sci Transl Med 2014;6:261ra153.
70. Klade CS, Schuller E, Boehm T, von Gabain A, Manns MP. Sustained viral load reduction in treatment-naive HCV genotype 1 infected patients after therapeutic peptide vaccination. Vaccine 2012;30:2943–2950.
71. Gowans EJ, Roberts S, Jones K, Dinatale I, Latour PA, Chua B, et al. A phase I clinical trial of dendritic cell immunotherapy in HCV-infected individuals. J Hepatol 2010;53:599–607.
72. Kelly C, Swadling L, Capone S, Brown A, Richardson R, Halliday J, et al. Chronic hepatitis C viral infection subverts vaccine-induced T-cell immunity in humans. Hepatology 2016;63:1455–1470.
73. Callendret B, Eccleston HB, Satterfield W, Capone S, Folgori A, Cortese R, et al. Persistent hepatitis C viral replication despite priming of functional CD8(+) T cells by combined therapy with a vaccine and a direct-acting antiviral. Hepatology 2016;63:1442–1454.
74. Grakoui A, Shoukry NH, Woollard DJ, Han JH, Hanson HL, Ghrayeb J, et al. HCV persistence and immune evasion in the absence of memory T cell help. Science 2003;302:659–662.
75. Wieland D, Thimme R. Vaccine-induced hepatitis C virus-specific CD8(+) T cells do not always help. Hepatology 2016;63:1411–1414.
76. Smyk-Pearson S, Tester IA, Klarquist J, Palmer BE, Pawlotsky JM, Golden-Mason L, Rosen HR. Spontaneous recovery in acute human hepatitis C virus infection: functional T-cell thresholds and relative importance of CD4 help. J Virol 2008;82:1827–1837.
77. Rehermann B. Cellular immune response to the hepatitis C virus. J Viral Hepat 1999;6(Suppl 1):31–35.
78. Liu L, Fisher BE, Dowd KA, Astemborski J, Cox AL, Ray SC. Acceleration of hepatitis C virus envelope evolution in humans is consistent with progressive humoral immune selection during the transition from acute to chronic infection. J Virol 2010;84:5067–5077.
79. Christie JM, Healey CJ, Watson J, Wong VS, Duddridge M, Snowden N, et al. Clinical outcome of hypogammaglobulinaemic patients following outbreak of acute hepatitis C: 2 year follow up. Clin Exp Immunol 1997;110:4–8.
80. Pestka JM, Zeisel MB, Blaser E, Schurmann P, Bartosch B, Cosset FL, et al. Rapid induction of virus-neutralizing antibodies and viral clearance in a single-source outbreak of hepatitis C. Proc Natl Acad Sci U S A 2007;104:6025–6030.
81. Bartosch B, Verney G, Dreux M, Donot P, Morice Y, Penin F, et al. An interplay between hypervariable region 1 of the hepatitis C virus E2 glycoprotein, the scavenger receptor BI, and high-density lipoprotein promotes both enhancement of infection and protection against neutralizing antibodies. J Virol 2005;79:8217–8229.
82. Lai ME, Mazzoleni AP, Argiolu F, De Virgilis S, Balestrieri A, Purcell RH, et al. Hepatitis C virus in multiple episodes of acute hepatitis in polytransfused thalassaemic children. Lancet 1994;343:388–390.
83. Chung RT, Gordon FD, Curry MP, Schiano TD, Emre S, Corey K, et al. Human monoclonal antibody MBL-HCV1 delays HCV viral rebound following liver transplantation: a randomized controlled study. Am J Transplant 2013;13:1047–1054.
84. Lanphear BP, Linnemann CC, Jr., Cannon CG, DeRonde MM, Pendy L, Kerley LM. Hepatitis C virus infection in healthcare workers: risk of exposure and infection. Infect Control Hosp Epidemiol 1994;15:745–750.
85. Alter MJ. The epidemiology of acute and chronic hepatitis C. Clin Liver Dis 1997;1:559–568, vi-vii.
86. U.S. Public Health Service. Updated U.S. Public Health Service Guidelines for the Management of Occupational Exposures to HBV, HCV, and HIV and Recommendations for Postexposure Prophylaxis. MMWR Recomm Rep 2001;50:1–52.
87. Henderson DK. Managing occupational risks for hepatitis C transmission in the health care setting. Clin Microbiol Rev 2003;16:546–568.
88. Guedj J, Dahari H, Rong L, Sansone ND, Nettles RE, Cotler SJ, et al. Modeling shows that the NS5A inhibitor daclatasvir has two modes of action and yields a shorter estimate of the hepatitis C virus half-life. Proc Natl Acad Sci U S A 2013;110:3991–3996.